Calendario›REGN›DUPIXENT® · AROMA

DUPIXENT® · AROMA

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Chronic Rhinosinusitis With Nasal Polyposis (del registro, en inglés).

Fase

no aplica

Estado

En marcha, sin reclutar

Participantes

717

previstos

Centros

81

Fin del objetivo primario

mar 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en ago 2021.

Qué mide

Baseline Patient Characteristics (Baseline up to 3 years) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe primary objectives of the study are: * To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time. * To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities The secondary objectives of the study are: * To characterize real-world utilization of DUPIXENT® for patients with CRSwNP * To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP * To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04959448), actualizada en jul 2026.